TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33064803

Group type: EXPERIMENTAL
Intervention: Sleep group (n=101)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Wake group (n=35)
Number of subjects: 136
Study: 36331670

Group type: EXPERIMENTAL
Intervention: 30 mg morphine sulfate ODT
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 10 mg morphine sulfate ODT
Number of subjects: 104

Group type: COMPARATOR
Intervention: 10 mg morphine sulfate tablet (Sevredol®)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 30 mg morphine sulfate tablet (Sevredol®)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 30 mg morphine sulfate capsule (Actiskenan®)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 30 mg morphine sulfate solution (Oramorph®)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 30 mg and 10 mg ODTs and tablets
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Product appreciation questionnaire
Number of subjects: 104
Study: 34067585

Group type: EXPERIMENTAL
Intervention: Self-prepared carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 28
Study: 33066469

Group type: EXPERIMENTAL
Intervention: Cooling Vest (VEST)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive Rest (PASS)
Number of subjects: 14
Study: 34226073

Group type: EXPERIMENTAL
Intervention: Nebulized ketamine 0.75 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nebulized ketamine 1 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nebulized ketamine 1.5 mg/kg
Number of subjects: 120
Study: 33140457

Group type: EXPERIMENTAL
Intervention: PHY906 plus capecitabine (750 mg/m2 capecitabine b.i.d. for 14 days and 800 mg of PHY906 b.i.d. on days 1–4 and days 8–11 every 21-day cycle)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PHY906 plus capecitabine
Number of subjects: 39
Study: 35049373

Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution, 1 drop, 6 times per day for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate preservative-free artificial tears, 1 drop, 6 times per day for 4 weeks
Number of subjects: 30
Study: 34431764

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium longum subsp. infantis BB‐02, Bifidobacterium animalis subsp. lactis BB‐12, Streptococcus thermophilus TH‐4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation commenced before 5 days from birth
Number of subjects: 0
Study: 35194005

Group type: EXPERIMENTAL
Intervention: G‐chemo
Number of subjects: 58

Group type: COMPARATOR
Intervention: R‐chemo
Number of subjects: 58
Study: 32676739

Group type: EXPERIMENTAL
Intervention: COVID original articles published in the TOP-10 journals
Number of subjects: 100

Group type: COMPARATOR
Intervention: Opinion articles
Number of subjects: 100
Study: 33909213

Group type: EXPERIMENTAL
Intervention: Storytelling with social contextual information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Storytelling without social contextual information
Number of subjects: 0
Study: 33045402

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (loading dose, then 3200 IU/day)
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2700
Study: 32729244

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 154
Study: 35256443

Group type: EXPERIMENTAL
Intervention: Intended delivery at health facility (HF)
Number of subjects: 39679

Group type: EXPERIMENTAL
Intervention: Intended delivery at home
Number of subjects: 39679

Group type: EXPERIMENTAL
Intervention: Age 25-34 and ≥35 years delivering at home
Number of subjects: 39679

Group type: EXPERIMENTAL
Intervention: Women delivering at HFs with primary schooling
Number of subjects: 39679

Group type: EXPERIMENTAL
Intervention: Women delivering at HFs with more than primary education
Number of subjects: 39679

Group type: EXPERIMENTAL
Intervention: Literate women delivering at HFs
Number of subjects: 39679

Group type: EXPERIMENTAL
Intervention: Women not in the lowest quintile of the wealth index delivering at HFs
Number of subjects: 39679
Study: 34309480

Group type: EXPERIMENTAL
Intervention: Hypnosis audio-recording intervention (4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study: 34400404

Group type: EXPERIMENTAL
Intervention: modified BLS (m-BLS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: conventional BLS (c-BLS)
Number of subjects: 108
Study: 32947541

Group type: EXPERIMENTAL
Intervention: Balloon Compression (BC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Radiofrequency (RF)
Number of subjects: 33
Study: 34405875

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Single arterial grafting (SAG)
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Multiple arterial grafting (MAG)
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Multiple arterial grafting (MAG) vs PCI
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Single arterial grafting (SAG) vs PCI
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Multiple arterial grafting (MAG) in 3VD vs PCI
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Single arterial grafting (SAG) in 3VD vs PCI
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Multiple arterial grafting (MAG) in LMCAD vs PCI
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Single arterial grafting (SAG) in LMCAD vs PCI
Number of subjects: 1743
Study: 34018052

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (LC) diet
Number of subjects: 115

Group type: COMPARATOR
Intervention: High-carbohydrate (HC) diet
Number of subjects: 115
Study: 33238279

Group type: EXPERIMENTAL
Intervention: Accumulated air pollution exposure (measured using the DEHM/UBM/AirGIS model system)
Number of subjects: 33723
Study: 33106180

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide, ceftriaxone, and paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35482522

Group type: EXPERIMENTAL
Intervention: School-based interventions (including cognitive behavioural therapy)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) based interventions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: School-based interventions
Number of subjects: 15
Study: 33070053

Group type: EXPERIMENTAL
Intervention: Gefitinib plus olaparib (250 mg gefitinib daily + 200 mg olaparib three times daily)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Gefitinib alone (250 mg daily)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Gefitinib plus olaparib
Number of subjects: 182

Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 182
Study: 35473740

Group type: EXPERIMENTAL
Intervention: Low-dose prophylactic anticoagulation (PA)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: High-dose prophylactic anticoagulation (HD-PA)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation (TA)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Low-dose PA, HD-PA, or TA (combined)
Number of subjects: 353
Study: 33540340

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 956
Study: 34654623

Group type: EXPERIMENTAL
Intervention: IVIM-DWI parameters and texture parameters of primary lesions
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: IVIM-DWI parameters and texture parameters of lymph nodes
Number of subjects: 143
Study: 33640355

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 280

Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 280
Study: 34286397

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids capsule along with standard care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 60
Study: 34909899

Group type: EXPERIMENTAL
Intervention: Endoscopic transsphenoidal pituitary surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Microscopic transseptal pituitary surgery
Number of subjects: 46
Study: 34255034

Group type: EXPERIMENTAL
Intervention: 15 μg cholecalciferol daily for 12 weeks (with UVB exposure)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15 μg cholecalciferol daily for 12 weeks (without UVB exposure)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (with UVB exposure)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (without UVB exposure)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15 μg cholecalciferol (both groups)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15 μg cholecalciferol
Number of subjects: 100
Study: 33259542

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 9198

Group type: COMPARATOR
Intervention: Comparison group (age-matched women without hysterectomy)
Number of subjects: 9198
Study: 35760910

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg daily
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (hydration only)
Number of subjects: 97
Study: 34465955

Group type: EXPERIMENTAL
Intervention: Povidone-iodine intrarectal disinfection
Number of subjects: 621

Group type: COMPARATOR
Intervention: Formalin needle disinfection
Number of subjects: 621
Study: 36215853

Group type: EXPERIMENTAL
Intervention: Enhanced ambulatory care competencies through didactic content and clinical experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulations as part of the training
Number of subjects: 0
Study: 34297067

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU/d)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 372
Study: 32056816

Group type: EXPERIMENTAL
Intervention: IC with modified contract‐relax proprioceptive neuromuscular facilitation (PNF) stretching
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IC with myofascial release
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IC with static stretching
Number of subjects: 40
Study: 34791262

Group type: EXPERIMENTAL
Intervention: Seltorexant 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33397313

Group type: EXPERIMENTAL
Intervention: Improved baking stove intervention
Number of subjects: 5508

Group type: COMPARATOR
Intervention: Continuation of open burning traditional baking stove
Number of subjects: 5508
Study: 35704592

Group type: EXPERIMENTAL
Intervention: Normal chart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misleading chart
Number of subjects: 0
Study: 34161143

Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 33844367

Group type: EXPERIMENTAL
Intervention: Intervention organs
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low risk to the kidney from the intervention
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Younger donor age
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Longer time until the next organ offer
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Greater trust in their transplant physician
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Waitlisted longer
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Being Black
Number of subjects: 249
Study: 32662209

Group type: EXPERIMENTAL
Intervention: Boric acid impregnated sponge combined with NPWT system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Silver nitrate sponge
Number of subjects: 100
Study: 35055339

Group type: EXPERIMENTAL
Intervention: Farmalarm app (experimental group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard follow-up (control group)
Number of subjects: 150
Study: 33059607

Group type: EXPERIMENTAL
Intervention: Vi-diphtheria toxoid typhoid conjugate vaccine (Vi-DT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vi-polysaccharide vaccine (Vi-PS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vi-DT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vi-PS
Number of subjects: 200
Study: 33559711

Group type: EXPERIMENTAL
Intervention: PET/CT-based CNN models
Number of subjects: 197

Group type: COMPARATOR
Intervention: CT-based CNN models
Number of subjects: 197

Group type: COMPARATOR
Intervention: PET-based CNN models
Number of subjects: 197

Group type: COMPARATOR
Intervention: Manual assessment by oncologist
Number of subjects: 197
Study: 36443713

Group type: EXPERIMENTAL
Intervention: 82Rb PET/CT after amino acid-infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: 82Rb PET/CT before amino acid-infusion (baseline)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 82Rb PET/CT scans on Day A and Day B
Number of subjects: 17
Study: 34404427

Group type: EXPERIMENTAL
Intervention: 1 Hz taVNS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pre-taVNS resting state
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20 Hz taVNS
Number of subjects: 24
Study: 34171556

Group type: EXPERIMENTAL
Intervention: Storytelling sessions based on emotional stories
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Storytelling sessions based on referential stories
Number of subjects: 35
Study: 36117055

Group type: EXPERIMENTAL
Intervention: Oral treprostinil (TRE)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study: 35340949

Group type: EXPERIMENTAL
Intervention: 1 mg nalbuphine (group N)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 25 μg fentanyl (group F)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 0.9% normal saline (group C)
Number of subjects: 66
Study: 32172198

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 2000 mg/day
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 34749724

Group type: EXPERIMENTAL
Intervention: Surgical exposure of impacted canines with dissected dental follicle (DF) stitching to muscle and mucosa
Number of subjects: 24

Group type: COMPARATOR
Intervention: Contralateral unimpacted canines
Number of subjects: 24
Study: 32594478

Group type: EXPERIMENTAL
Intervention: Internet Behavior Therapy (IBT, n=51)
Number of subjects: 101

Group type: COMPARATOR
Intervention: e-mail education (EE, n=50)
Number of subjects: 101
Study: 34996788

Group type: EXPERIMENTAL
Intervention: Guideline-based intervention including educational outreach visit, computerized decision tool, and self-management application for patients.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Guideline-based intervention
Number of subjects: 36
Study: 33691451

Group type: EXPERIMENTAL
Intervention: Lymph node metastasis (LNM) nomogram
Number of subjects: 22403

Group type: EXPERIMENTAL
Intervention: Distant metastasis nomogram
Number of subjects: 22403
Study: 33023684

Group type: EXPERIMENTAL
Intervention: IVB nitroglycerin (NTG)
Number of subjects: 44
Study: 35685573

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/day for eight weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received standard treatment for analgesia (oral diclofenac 75 mg/12 h as needed)
Number of subjects: 60
Study: 34770611

Group type: EXPERIMENTAL
Intervention: Concurrent visual feedback
Number of subjects: 19

Group type: COMPARATOR
Intervention: Terminal visual feedback
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Removal of concurrent feedback
Number of subjects: 19

Group type: COMPARATOR
Intervention: Concurrent vs Terminal feedback
Number of subjects: 19
Study: 34701886

Group type: EXPERIMENTAL
Intervention: NACT+CCRT
Number of subjects: 97

Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 97
Study: 32255395

Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 34114223

Group type: EXPERIMENTAL
Intervention: Psychoeducation and music intervention
Number of subjects: 62
Study: 32833475

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training (CBMT) intervention delivered via an 8-session, at-home, electronic tablet.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training (CBMT) intervention
Number of subjects: 0
Study: 34664109

Group type: EXPERIMENTAL
Intervention: 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 240 mg CBD, 10.8 mg THC, and 13.2 mg CBC daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 360 mg CBD, 16.2 mg THC, and 19.8 mg CBC daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 480 mg CBD, 21.6 mg THC, and 26.4 mg CBC daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All doses of CBD, THC, and CBC
Number of subjects: 43
Study: 35730901

Group type: EXPERIMENTAL
Intervention: Bilateral movement-based computer games + conventional rehabilitation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Video-directed exercise + conventional rehabilitation (control group)
Number of subjects: 93
Study: 32600393

Group type: EXPERIMENTAL
Intervention: Histamine-2 receptor antagonist (H2RA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 35369704

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided PCI
Number of subjects: 1500

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1500
Study: 34798895

Group type: EXPERIMENTAL
Intervention: Minor Ailment Service (MAS)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 808
Study: 33299898

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Second IVIG treatment
Number of subjects: 80
Study: 36194219

Group type: EXPERIMENTAL
Intervention: Opioid-sparing protocol (naproxen, acetaminophen, pantoprazole, limited hydromorphone, educational infographic)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (opioid analgesic)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Opioid-sparing protocol
Number of subjects: 200
Study: 33472391

Group type: EXPERIMENTAL
Intervention: CBT Grief-Help
Number of subjects: 134

Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 134
Study: 32702101

Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg per day) for 4 weeks followed by 10 weeks of meloxicam
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo followed by CBT for 10 weeks
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo followed by CBT
Number of subjects: 364
Study: 35318752

Group type: EXPERIMENTAL
Intervention: Immediate implant with immediate provisional restoration and socket preservation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Early implant placement with guided bone regeneration and delayed loading
Number of subjects: 50
Study: 32324435

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15, surgery planned on day 29.
Number of subjects: 39
Study: 35822829

Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) intervention involving structured conversations led by skilled nurses after a two-day training session.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information brochure provided to participants as part of the intervention.
Number of subjects: 0
Study: 32315342

Group type: EXPERIMENTAL
Intervention: Essential new-born care practices
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Safe cord care practice
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Optimal thermal care practices
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Good neonatal feeding practices
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Antenatal Care (ANC) visits
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Knowledge of essential new-born care
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Counselled about essential new-born care
Number of subjects: 417
Study: 35695753

Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine 40 mg in Group 1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine 35 mg in Group 2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine 45 mg in Group 3
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine (varied doses based on CRM)
Number of subjects: 120
Study: 33714527

Group type: EXPERIMENTAL
Intervention: oAPBI (once daily)
Number of subjects: 113

Group type: COMPARATOR
Intervention: tAPBI (twice daily)
Number of subjects: 113
Study: 32741071

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.025 mg/kg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.050 mg/kg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.075 mg/kg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.100 mg/kg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sham group (normal saline)
Number of subjects: 210
Study: 35092948

Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU tablet)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 34794426

Group type: EXPERIMENTAL
Intervention: Personalized depression risk score
Number of subjects: 40
Study: 34867829

Group type: EXPERIMENTAL
Intervention: Liothyronine (LT3)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Levothyroxine (LT4)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both LT3 and LT4
Number of subjects: 59
Study: 32005971

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) insertion before the last quadrant emulsification (Group III, n=130)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Standard setting (Group I, n=134)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Reduced vacuum and flow rate (Group II, n=137)
Number of subjects: 401
Study: 34651505

Group type: EXPERIMENTAL
Intervention: Plyometric training with feedback (FB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Plyometric training with taping (TP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (regular team schedule)
Number of subjects: 48